Medicine shortages are reshaping pharmaceutical supply chains across Europe and Ireland is acutely exposed. The Framework Agreement on the Supply and Pricing of Medicines 2026–2029, signed on 3 March 2026 between the Irish government and Medicines for Ireland (MFI), introduces a value maintenance realignment to address the pricing root causes of essential medicine shortages. The provision acknowledges that below-cost reimbursement is a supply risk, not a convenience.

The MFI agreement treats supply security as a structural challenge requiring structural remedies. The value maintenance realignment is not an industry concession; it is a pragmatic response to evidence that price suppression drives market exit. The framework merits commendation: it names the problem, applies a proportionate correction, and embeds the mechanism in governance structures permitting review.

Ireland is more exposed to medicine shortages than any comparable EU member state. Irish Pharmacist reports that Ireland has more single-supplier medicines than any other EU country, leaving the system without redundancy when a manufacturer encounters difficulty. The 2025 IPU Medicine Shortages Survey found that 57% of pharmacists reported a significant increase in shortages, with the same proportion managing 41 or more concurrent shortages. The withdrawal of salbutamol nebules was linked to HSE pricing, while the product remained available in higher-priced markets.

European data reinforces urgency. Teva Pharmaceuticals Europe research from February 2025 found that 46% of critical generic medicines across the EU rely on a single manufacturer, with consolidation advancing three times faster than in the broader generics sector. Some 30% of critical generics marketed in 2014 had been withdrawn by 2024, rising to 37% in oncology and cardiology. European generic prices fell approximately 8% over the past decade while consumer prices rose 30%, creating a gap between reimbursement and production costs forcing market exit.

The MFI agreement responds with a Schedule 3 list of 44 essential medicines, covering oncology agents, antibiotics, and antifungals, each eligible for a 1.5% per annum uplift. Suppliers may also seek an urgent price increase under Clause 13 where a material cost impact threatens supply, with the HSE required to respond within 60 days. The Clause 7.5 tiered pricing mechanism permits generics to enter niche markets below approximately €2 million at up to 70% of the reference originator price, making otherwise uneconomic supply viable.

Three actions will amplify the framework. Suppliers should audit portfolios against Schedule 3 and initiate value maintenance applications without delay, as uptake is essential to the mechanism delivering value. The HSE should expand Schedule 3 proactively, using HPRA shortage notifications as the basis for additions rather than awaiting annual reviews. Industry and the Department of Health should engage with the EU Critical Medicines Act to ensure Irish supply data shapes the solidarity mechanism the Act proposes.

The MFI agreement value maintenance mechanism is a targeted and overdue instrument. Embedded within HSE procurement and expanded as the essential medicines landscape evolves, it can narrow Ireland exposure to single-source supply risk. A pricing-to-shortage dynamic is driving global reform; Ireland has a domestic framework aligned with that international direction.

(The views expressed by the writer are his/her own and do not necessarily reflect the views or positions of BusinessRiver.)